Price
No data yet.
Social Signal Score
Revenue
$99.31MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Frederick G. Vogt
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 975
- Beta
- 0.70
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 7.25
Financials
Revenue
$99.31M+41628.2%Net Income
$-47.31MEBITDA
$-39.19MFree Cash Flow
$-66.28MEPS (diluted)
$-0.11Shares Outstanding (diluted)
450.19M+189.5%Operating Expenses
$63.93MCash & Debt
$297.67MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $263.50M | $-390.98M | $-1.09 |
| 2024 | $164.07M | $-372.18M | $-1.28 |
| 2023 | $1.19M | $-444.04M | $-1.89 |
| 2022 | $0.00 | $-395.89M | $-2.49 |
| 2021 | $0.00 | $-342.25M | $-2.23 |
| 2020 | $0.00 | $-259.58M | $-1.88 |
| 2019 | $0.00 | $-197.56M | $-1.50 |
| 2018 | $0.00 | $-123.58M | $-1.27 |
| 2017 | $0.00 | $-92.06M | $-1.41 |
| 2016 | $0.00 | $-52.89M | $-0.96 |
| 2015 | $0.00 | $-27.66M | $-0.62 |
| 2014 | $0.00 | $-12.04M | $-0.48 |
| 2013 | $0.00 | $-25.38M | $-2.60 |
| 2012 | $0.00 | $-3.31M | $-4.14 |
Valuation
IOVAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
105Social Signal Score
Mentions (1)
- Newsseekingalpha.com·6h ago·Neutral
…atalysts Ahead, And Competitor Updates Iovance Biotherapeutics, Inc. delivered a breakout Q2 '26 for Amtagvi sales, with management guiding for further growth ahead. IOVA's maturing clinical pipeline and imminent NSCLC readout position the company for further upside, given the market potential in NSCLC is several times larger than in melanoma. Potential competitor, IMTX, is expecting to produce results from a trial of its cell therapy, Anzu-cel, in melanoma in H1 '27.
View source ↗
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $-0.10 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.11 vs $-0.13beat
- Thu, May 7$-0.19 vs $-0.19beat
- Tue, Feb 24$-0.18 vs $-0.22beat
- Thu, Nov 6$-0.25 vs $-0.29beat
- Thu, Aug 7$-0.33 vs $-0.29miss
- Thu, May 8$-0.36 vs $-0.25miss
Estimates and results for IOVA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IOVA officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.